RBC Capital Maintains Outperform on Chemours, Lowers Price Target to $28
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Arun Viswanathan maintains an Outperform rating on Chemours (NYSE:CC) but lowers the price target from $35 to $28.
October 11, 2024 | 5:48 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
RBC Capital maintains an Outperform rating on Chemours but lowers the price target from $35 to $28, indicating a more cautious outlook.
The maintenance of an Outperform rating suggests continued confidence in Chemours' performance, but the lowered price target indicates a more cautious outlook, likely due to market conditions or company-specific factors. This could lead to short-term downward pressure on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100